A hormonal disorder where the body makes too much cortisol from internal causes, usually a tumor in the pituitary gland or adrenal glands, rather than from steroid medications. It matters to investors because its diagnosis, treatment options, clinical trial results, and regulatory approvals can affect pharmaceutical and medical-device companies’ revenues and valuation; think of it as a small but specialized market shaped by clinical outcomes and reimbursement decisions.
severe hypoglycemiamedical
Severe hypoglycemia is an episode of dangerously low blood sugar that leaves a person unable to treat themselves and typically requires assistance from another person or emergency medical care. Think of it like a car suddenly losing power: it can cause confusion, fainting, seizures or unconsciousness and carries immediate health and liability risks. For investors it matters because frequency and severity affect a treatment’s safety record, regulatory approval, reimbursement, trial outcomes and market acceptance.
primary periodic paralysismedical
A rare inherited muscle disorder that causes sudden, temporary episodes of muscle weakness or paralysis when the balance of potassium in the blood shifts; think of it as a brief power outage in the body’s muscles triggered by changes in minerals or certain foods, activity, or temperature. It matters to investors because its chronic, episodic nature creates specific medical needs, influences the size and urgency of the treatment market, shapes clinical trial design and regulatory risk for therapies, and can affect long‑term healthcare costs and adoption of new drugs or devices.
subcutaneous injectionmedical
A subcutaneous injection is a method of delivering a medicine or vaccine by inserting a small needle just under the skin into the thin layer of fat beneath the outer skin. For investors, administration by subcutaneous injection matters because it influences patient convenience, dosing frequency, manufacturing complexity and distribution costs, all of which affect how widely a treatment is adopted and how it is priced—like choosing a product that customers can easily use at home versus one that needs a clinic visit.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results.
Interested parties may pre-register for the call here or via the “Events” section of the Investor Relations website. It is recommended that attendees register 15 minutes prior to the scheduled webcast.
Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.
